Duchenne Muscular Dystrophy Case Study
Uploaded by
jadenDuchenne Muscular Dystrophy Case Study
Uploaded by
jadenCommon questions
Powered by AIAs Duchenne Muscular Dystrophy progresses, muscle weakness affects proximal muscles essential for stability and movement, leading to significant mobility challenges. The weakening of the muscles in the pelvic area, thighs, and upper body makes activities such as standing up, walking, and climbing stairs difficult. Over time, reduced mobility can result in scoliosis, further complicating physical mobility and leading to wheelchair dependence in most patients as the disease advances .
The absence of dystrophin causes muscle fibers in Duchenne Muscular Dystrophy (DMD) patients to become fragile and easily damaged. Dystrophin is a protein that strengthens muscle fibers and protects them from injury during muscle contractions. Without it, muscle fibers deteriorate over time, leading to progressive muscle weakness and wasting. This primarily affects boys since the dystrophin gene is located on the X chromosome, and boys have only one X chromosome, causing them to manifest symptoms with just one mutated copy of the gene .
Pseudohypertrophy in Duchenne Muscular Dystrophy presents a clinical challenge as it may give a misleading impression of muscular health. Although affected muscles, such as the calves, appear enlarged, this is due to fat and connective tissue accumulation rather than muscle development. This false enlargement can lead to misinterpretation in clinical assessments, potentially delaying accurate diagnosis if not combined with comprehensive evaluations like muscle strength testing and biomarkers such as creatine kinase levels .
Duchenne Muscular Dystrophy is caused by a genetic mutation in the dystrophin gene located on the X chromosome. Boys, who have one X and one Y chromosome, will develop the disease if their single X chromosome carries the mutated gene. Girls, on the other hand, have two X chromosomes, so a mutation in one X chromosome generally does not express the disease due to the presence of a normal, functioning gene on the other X chromosome. Thus, girls are typically carriers but do not exhibit symptoms .
Recent FDA approvals, such as that of Duvyzat (givinostat), have provided new avenues in the management of Duchenne Muscular Dystrophy. Unlike corticosteroids, givinostat is a non-steroidal medication that alters gene expression, potentially slowing disease progression more effectively and increasing patient mobility. This advancement suggests a shift towards targeted treatments that modify disease mechanisms at a genetic level, promising improved long-term outcomes and quality of life for patients while potentially setting the stage for future gene-based therapies .
Patients with Duchenne Muscular Dystrophy present with progressive muscle weakness which begins in early childhood, typically affecting the proximal muscles near the trunk, including the upper legs, pelvic area, upper arms, and shoulders. As the disease progresses, it impacts the respiratory muscles leading to breathing difficulties and cardiac muscles affecting heart function. An associated condition is pseudohypertrophy, where muscles such as the calves appear enlarged due to fat and connective tissue accumulation, not true muscle growth .
The current standard of care for Duchenne Muscular Dystrophy mainly focuses on managing symptoms to slow disease progression, often involving corticosteroids to help preserve muscle function temporarily. However, this approach does not address the underlying genetic cause, and the disease continues to progress. Patients still face inevitable loss of mobility, respiratory issues, and eventual heart complications. The standard treatments do not halt muscle degeneration, primarily managing symptoms and significantly impacting quality and quantity of life .
In Duchenne Muscular Dystrophy, scoliosis progression is more rapid with angulation increasing between 16° and 24° per year, especially during the adolescent growth spurt. The scoliosis shape commonly exhibits thoracolumbar kyphosis rather than the lordosis seen in adolescent idiopathic scoliosis. This results from muscle weakness and alterations in trunk alignment due to progressing muscle degeneration. The apex of scoliosis in DMD patients often develops at the thoracolumbar junction, potentially leading to additional complications like pelvic obliquity .
A creatine kinase (CK) test is commonly used to indicate muscle damage in Duchenne Muscular Dystrophy. CK is an enzyme found in muscle tissue, and elevated levels in the blood suggest damage or degeneration of muscle cells. In DMD patients, muscle fiber breakdown releases CK into the bloodstream, leading to abnormally high CK levels. This finding, combined with clinical symptoms, supports the diagnosis of DMD .
Future treatment strategies for Duchenne Muscular Dystrophy include advanced gene therapy approaches using Cas9 technology to correct the genetic mutation responsible for the disease. This could provide a more effective and permanent treatment compared to current options that mostly focus on symptom management using medications like corticosteroids. Targeted delivery systems are also being explored to enhance gene therapy precision, ensuring it reaches affected muscle tissues, potentially allowing for earlier intervention, reducing disease progression, and improving quality of life. Recently, the FDA approved Duvyzat (givinostat), a non-steroidal drug, which alters gene expression and slows disease progression in children and adolescents with DMD .